Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-05-17
2005-05-17
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C530S387300, C530S388220
Reexamination Certificate
active
06893636
ABSTRACT:
Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
REFERENCES:
patent: 4940782 (1990-07-01), Rup et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5543144 (1996-08-01), Chang
patent: 5585089 (1996-12-01), Queen et al.
patent: 5635600 (1997-06-01), Fanger et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5648267 (1997-07-01), Reff
patent: 5658570 (1997-08-01), Newman et al.
patent: 5736137 (1998-04-01), Anderson
patent: 5811524 (1998-09-01), Brams et al.
patent: 6001358 (1999-12-01), Black et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: WO 8707302 (1987-12-01), None
patent: WO 8806891 (1988-09-01), None
patent: WO 8900138 (1989-01-01), None
patent: WO 9217707 (1992-10-01), None
patent: WO 9302108 (1993-02-01), None
patent: WO 9612741 (1996-05-01), None
patent: WO 9612742 (1996-05-01), None
Skolnick et al, Trends in Biotech 18(1):34-35, Jan. 2000.*
Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.*
Van Noort et al. International Reivew of Cytology 178: 127-205, 1998.*
The Merch manual of Diagnosis and Therapy, Seventeenth Edition, 1999, pp. 416-122.*
Ngo et al. The Protein Folding Problem and Tertiary Structure Prediction. Merz & LeGrand, Eds., Birkhauser Boston, pp. 491-495, 1994.*
Paul et al. Fundamental Immunology. 2nd Edition, Raven Press, New York, pp. 705 and 870, 1989.*
Wakai et al. Hybridoma, vol. 12, pp. 25-43, 1993.*
Saxon et al. J. Immunol. vol. 147, pp. 4000-40006, 1991.*
Boulet et al., “Inhibitory Effects of an Anti-Ige Antibody E25 on Allergen-induced Early Asthmatic Response,”Am J Respir Crit Care Med, (1997) 155:1835-44.
Casale et al., “Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis,”J Allergy Clin Immunol, (1997), 100:110-120.
Coyle et al., “Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infiltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody,”J Exp Med, (1996), 183:1303-1310.
Fahy et al., “The Effect of an Anti-IgE Monoclonal Antibody on the Early-and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects,”Am J Respir Crit Care Med, (1997), 155:1828-34.
Ohashi et al., “Immunotherapy Affects the Seasonal Increase in Specific IgE and Interleukin-4 in Serum of Patients with Seasonal Allergen Rhinitis,”Scan J Immunol, (1997), 46(1):67-77.
Ohashi et al., “Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis,”Annals of Allergy, Asthma, and Immunol, (1997), 79:213-220.
Ohashi et al., “Ten-Year Follow-Up Study of Allergic-Specific Immunoglobulin E and Immunoglobulin G4, Soluble Interleukin-2 Receptor, Interleukin-4, Soluble Intercellular Adhesion Molecule-1 and Soluble Vascular Cell Adhesion Molecule-1 in Serum of Patients on Immunotherapy for Perennial Allergic Rhinitis,”Scand J Immunol, (1998), 47:167-178.
Peebles et al., “Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation,”J Allergy Clin Immunol, (1998), 101:265-273.
Pullerits et al., “An intranasal glucocorticoid inhibits the increase of specific IgE intiated during birch pollen season,”J Allergy Clin Immunol, (1997), 100:601-605.
Ward E.S. and Ghetie V., “The effector functions of immunoglobulins: implications for therapy,” 1995,Therapeutic Immunology, 2:77-94.
Luo et al., “Cross-linking of CD23 antigen by its natural ligand (IgE) or by anti-CD23 antibody prevents B lymphocyte proliferation and differentiation”, J. Immunol., 146(7):2122-9 (1991).
Groves et al., “Production of an ovine monoclonal antibody to testosterone by an interspecies fusion”, Hybridoma, vol. 6(1):71 (1987).
Robbins, Pathologic Basis of Disease, 5th Ed., ed. by Cotran et al., W.B. Saunders Co., Philadelphia, PA, 1994, pp. 197-199.
Seaver, Genetic Engineer News, 14(14): pp. 19, 21 (Aug., 1994).
Haak-Frendscho et al., “Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo”, Immunology, 82:306 (1994).
Delespesse et al., “Human IgE-binding factors”, Immunology Today 10:159, (1989).
Durum et al., “Proinflammatory Cytokines and Immunity,” in Fundamental Immunology, Third Edition, Chapter 21, ed. by Paul et al., Raven Press, Ltd., New York, p. 826 (1993).
Vercelli et al., “Induction of human IgE synthesis required interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens”, J. Exp. Med., 169:1295 (Apr. 1989).
Presta et al., “Humanization of an antibody directed against IgE”, J. Immunology, 151(5):2623 (Sep. 1993).
Strike et al., “Production of human-human hybridomas secreting antibody to sheep erythrocytes after in vitro immunization”, J. Immunol., 132(4): 1798 (Apr. 1984).
Cruse et al., Illustrated Dictionary of Immunology, CRC Press, Boca Raton, Fla., 1995, p. 69.
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy”, Nature, 337:525 (Feb. 1989).
Rector et al., “Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry”, Immunol., 55: 481-488 (1985).
Suemura et al., “Monoclonal anti-Fc epsilon receptor antibodies with different specificities and studies on th expression of Fc epsilon receptors on human B and T cells”, J. Immunol., 137: 1214-1220 (1986).
Noro et al., “Monoclonal antibody (H107) inhibiting IgE binding to Fc epsilon R(+) human lymphocytes”, J. Immunol., 137: 1258-1263 (1986).
Yu et al., “Negative feedback regulation of IgE synthesis by murine CD23”, Nature, 369: 753-756 (1994).
Bonnefoy et al., “Regulation of IgE synthesis by CD23/CD21 interaction”, Int. Arch. Allergy Immunol., 107: 40-42 (1995).
Aubry et al., “CD21 is a ligand for CD23 and regulates IgE production,” Nature, 358:505-507 (1992).
Bonnefoy et al., “Receptors for IgE”, Curr. Opin. Immunol., 5: 944-949 (1993).
Grosjean et al., “CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones”, Eur. J. Immunol., 24: 2982-2988 (1994).
Pene et al., “Interleukin 5 enhances interleukin 4-induced IgE production by normal human B cells. The role of soluble CD23 antigen”, Eur J. Immunol., 18: 929-935 (1988).
Saxon et al., “Soluble CD23 containing B cell supernatants induce IgE from peripheral blood B-lymphocytes and costimulate with interleukin-4 in induction of IgE”, J. Allergy Clin. Immunol., 86 (3 pt 1) 333-344 (1990).
Hassner and Saxon, “Isotype-specific human suppressor T cells for IgE synthesis activated by IgE-anti-IgE immune complexes”, J. Immunol., 132: 2844 (1984).
Carroll et al., “Mouse x human heterohybridomas as fusion partners with human B cell tumors”, J. Immunol. Methods 89: 61 (1986).
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes”, J. Immunol., 147: 86 (1991).
Bourget et al., “CD20 monoclonal antibodies decrease interleukin-4-stimulated expression of the low-affinity receptor for IgE (Fc epsilon RII/CD23) in h
Kloetzer William S.
Nakamura Takehiko
Reff Mitchell E.
Biogen Idec MA Inc.
Chan Christina
Huynh Phuong
Pillsbury & Winthrop LLP
LandOfFree
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456129